Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 11

1.

Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.

Denholt CL, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen M, Hansen PR, Gillings N, Kjær A.

Nucl Med Biol. 2011 May;38(4):509-15. doi: 10.1016/j.nucmedbio.2010.11.003. Epub 2011 Mar 1.

PMID:
21531288
2.

Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.

Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM.

J Nucl Med. 2010 Jun;51(6):967-72. doi: 10.2967/jnumed.109.068395. Epub 2010 May 19.

3.

Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Pines G, Köstler WJ, Yarden Y.

FEBS Lett. 2010 Jun 18;584(12):2699-706. doi: 10.1016/j.febslet.2010.04.019. Epub 2010 Apr 11. Review.

4.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
5.

The EGFRvIII variant in glioblastoma multiforme.

Gan HK, Kaye AH, Luwor RB.

J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. Review.

PMID:
19324552
6.

Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.

Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjaer A.

Biopolymers. 2009 Mar;91(3):201-6. doi: 10.1002/bip.21117.

PMID:
19107925
7.

Discovering and improving novel peptide therapeutics.

McGregor DP.

Curr Opin Pharmacol. 2008 Oct;8(5):616-9. doi: 10.1016/j.coph.2008.06.002. Epub 2008 Jul 16. Review.

PMID:
18602024
8.

Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.

Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, Old LJ, Toomre DK, Scott AM.

Neoplasia. 2007 Dec;9(12):1099-110.

9.

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. Epub 2007 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15965. Ritter, Gerd [added].

10.

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44. Epub 2003 Jan 6. Erratum in: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2163. Cavanee, Webster K [corrected to Cavenee, Webster K].

11.

Epidermal growth factor.

Carpenter G, Cohen S.

J Biol Chem. 1990 May 15;265(14):7709-12. Review. No abstract available.

Supplemental Content

Support Center